IOL Chemicals & Pharmaceuticals Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript IOL Chemicals & Pharmaceuticals Ltd filed with BSE on 20 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
IOL Chemicals and Pharmaceuticals reported Q1 FY27 revenue of Rs 756 crore, up 37% year-on-year, with EBITDA of Rs 111 crore and PAT of Rs 64.5 crore. Management attributed the growth to higher capacity utilization, an improved product mix, and continued diversification of the API portfolio beyond ibuprofen, with non-ibuprofen products now contributing 43% of pharmaceutical revenue versus 36% a year earlier. Exports rose to 28.5% of revenue from 24.4%, and management reiterated FY27 guidance of 15-20% revenue growth with an EBITDA margin of 14-15%.
Numbers mentioned
Revenue from operations: INR756 CR (Q1 FY27)
p. 4
“During quarter one of financial year ‘27, the company reported revenue from operations INR756 CR as compared to INR551 crores in quarter one of financial year ‘26, registering a year-on-year growth of 37 percentage.”
Pardeep Kumar Khanna, page 4 of the filed PDF · View the filing
EBITDA: INR111 crores (Q1 FY27)
p. 4
“On the operating front, EBITDA stood at INR111 crores compared with INR69.5 crores in quarter one of financial year ‘26, representing a growth of 60.7 percentage.”
Pardeep Kumar Khanna, page 4 of the filed PDF · View the filing
EBITDA margin: 14.6% (Q1 FY27)
p. 4
“EBITDA margin improved to 14.6 percentage compared with 12.4 percentage in the corresponding quarter.”
Pardeep Kumar Khanna, page 4 of the filed PDF · View the filing
PAT: INR64.5 crores (Q1 FY27)
p. 4
“Coming to the bottom line, PAT stood at INR64.5 crores compared with INR34 crores in quarter one of corresponding year, registering a growth of 89.9%.”
Pardeep Kumar Khanna, page 4 of the filed PDF · View the filing
PAT margin: 8.4% (Q1 FY27)
p. 4
“PAT margin consequently improved to 8.4 percentage compared with 6.1 percentage in quarter one of financial year ‘26.”
Pardeep Kumar Khanna, page 4 of the filed PDF · View the filing
Export contribution: 28.5% (Q1 FY27)
p. 4
“Our export contribution also increased to 28.5% of revenue compared with 24.4% in same quarter of last financial year, reflecting the continuous strengthening of our international business.”
Pardeep Kumar Khanna, page 4 of the filed PDF · View the filing
Non-ibu contribution to pharma revenue: 43% (Q1 FY27)
p. 3
“Non-ibu products contributed 43% of pharmaceutical revenue in Q1 FY27 compared with 36% in Q1 FY26, with revenue growing 67% year-on-year basis, and emerging as a key driver of growth in our pharma business.”
Abhay Raj Singh, page 3 of the filed PDF · View the filing
Triacetin revenue potential: INR120 crores per year
p. 14
“Around INR120 crores per year.”
Pardeep Kumar Khanna, page 14 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 15% to 20% · FY27
stated firmly by Pardeep Kumar Khanna
p. 5
“For financial year 27, we remain confident of delivering 15% to 20% revenue growth with an EBITDA margin in the range of 14% to 15% and exports contributing approximately 25% to 30% of the revenue.”
Pardeep Kumar Khanna, page 5 of the filed PDF · View the filing
EBITDA margin — 14% to 15% · FY27
stated firmly by Pardeep Kumar Khanna
p. 5
“For financial year 27, we remain confident of delivering 15% to 20% revenue growth with an EBITDA margin in the range of 14% to 15% and exports contributing approximately 25% to 30% of the revenue.”
Pardeep Kumar Khanna, page 5 of the filed PDF · View the filing
Export contribution — 25% to 30% · FY27
stated firmly by Abhay Raj Singh
p. 5
“So, I think we are targeting this year around 25% to 30% range of the export revenues and we are hopeful that we will achieve it.”
Abhay Raj Singh, page 5 of the filed PDF · View the filing
Revenue growth — 15% to 20% · FY28
stated conditionally by Pardeep Kumar Khanna
p. 10
“Definitely, we have a plan to grow about 15% to 20% in top line and EBITDA to 15% to 17% in '28 approximately.”
Pardeep Kumar Khanna, page 10 of the filed PDF · View the filing
EBITDA margin — 15% to 17% · FY28
stated conditionally by Pardeep Kumar Khanna
p. 10
“Definitely, we have a plan to grow about 15% to 20% in top line and EBITDA to 15% to 17% in '28 approximately.”
Pardeep Kumar Khanna, page 10 of the filed PDF · View the filing
Paracetamol capacity utilization — around 70% · by end of FY27
stated as an aspiration by Abhay Raj Singh
p. 5
“And as of now we are operating at around 55% of enhanced capacity, which we expect, by the end of this financial year, will be reaching to around 70%.”
Abhay Raj Singh, page 5 of the filed PDF · View the filing
Non-ibuprofen contribution to pharma revenue — around 50% · near term
stated as an aspiration by Abhay Raj Singh
p. 8
“See, what we are expecting in the near term this business vertical should achieve around 50% overall contribution into the pharma.”
Abhay Raj Singh, page 8 of the filed PDF · View the filing
Non-ibu segment contribution to API segment — 50% to 55% · FY29
stated as an aspiration by Rakesh Mahajan
p. 9
“For FY '29 only after three to four years, we are expecting that non-Ibu segment will contribute around 50% to 55% of our API segment with good margin equivalent to the other Ibuprofen margins.”
Rakesh Mahajan, page 9 of the filed PDF · View the filing
Regulatory approvals for Triacetin — two to three quarters
stated as an aspiration by Abhay Raj Singh
p. 14
“It takes few quarters to reach the maturity for a product, and I think we will be get it in two, three quarters.”
Abhay Raj Singh, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said paracetamol capacity utilization is at 55% and expected to reach 70% by year end, with growing domestic and export demand.
Answered by Abhay Raj Singh
Asked by Abu Rafe: What is the outlook for paracetamol given weak demand in recent years?
p. 5
“And as of now we are operating at around 55% of enhanced capacity, which we expect, by the end of this financial year, will be reaching to around 70%.”
Abhay Raj Singh, page 5 of the filed PDF · View the filing
Management attributed the higher margin to capacity utilization, product mix, operational efficiencies and non-ibu segment demand.
Answered by Pardeep Kumar Khanna
Asked by Pahel Sharma: With Q1 EBITDA margin already ahead of FY27 guidance, what could sustain or moderate margins going forward?
p. 6
“We have achieved the EBITDA margin 14.6% in this quarter. And the key factor for this rise in EBITDA margin are higher capacity utilization, better product mix, operational efficiencies, and also stronger non-ibu segment API demand.”
Pardeep Kumar Khanna, page 6 of the filed PDF · View the filing
Management said the majority of growth was contributed by volume increase rather than price, without disclosing exact numbers.
Answered by Rakesh Mahajan
Asked by Vignesh: What proportion of pharma growth came from volume versus realization?
p. 6
“We can't say exact numbers, but as a, you can say calculation, the majority numbers contributed by the increase in the volume of our pharma products as compared to finished prices.”
Rakesh Mahajan, page 6 of the filed PDF · View the filing
Management said there was no inventory gain this quarter and attributed performance to operational factors instead.
Answered by Abhay Raj Singh
Asked by Jainam Ghelani: How much of this quarter's profitability was due to one-time inventory gains from the war-related price surge?
p. 8
“So basically, this is not due to the inventory gain, we might be having little bit inventory gain during the later part of the last quarter around 10 to 15 days, but this quarter we are not having inventory gain.”
Abhay Raj Singh, page 8 of the filed PDF · View the filing
Management said the EBITDA increase was primarily due to internal operational efficiencies rather than external factors or major product mix change.
Answered by Rakesh Mahajan
Asked by Soumya: How much of the EBITDA outperformance came from operating leverage versus product mix?
p. 9
“Increase in EBITDA margins primarily due to the operational efficiencies of existing product with increased capacity utilization, and there is no major product mix change except more penetration in the export market.”
Rakesh Mahajan, page 9 of the filed PDF · View the filing
Management said growth came from higher volumes, better pricing, and passing on increased input costs to customers amid healthy demand.
Answered by Pardeep Kumar Khanna
Asked by Maulik Varia: Why did growth appear muted in prior quarters and what triggered the revival?
p. 10
“So, Maulik, both top line and bottom-line growth was due to higher volumes along with better pricing of our established products as well as growth in new products.”
Pardeep Kumar Khanna, page 10 of the filed PDF · View the filing
Management said guidance remains unchanged though results could exceed it, but they do not want to upgrade the guidance.
Answered by Abhay Raj Singh
Asked by Shaikh Mohammed: Given Q1 outperformance, will the company raise its full-year top-line guidance of Rs 2,600-2,700 crore?
p. 13
“So I think the previous guidance when we've given, we taken into consideration of this whole year. So the guidance will be remaining in the same line. However, we will be able to -- having the current scenario, we think that we may cross that number. But we don't want to upgrade the guidance”
Abhay Raj Singh, page 13 of the filed PDF · View the filing
Risks flagged
Geopolitical uncertainty, supply chain challenges, and inflationary pressure on select raw materials
p. 4
“This progress is particularly encouraging against the backdrop of continued geopolitical uncertainties, supply chain challenges, and inflationary pressure across select raw materials.”
Abhay Raj Singh, page 4 of the filed PDF · View the filing
Dependence on China for DCDA raw material used in metformin production
p. 15
“we'll not be doing the backward integration, for the it we are depending for DCDA,a raw material. from China, and I think not only we, but most of the companies are also depending on the same from the China, because this is geographically available in that region.”
Abhay Raj Singh, page 15 of the filed PDF · View the filing
Guidance for FY28 could change if the business scenario shifts
p. 10
“Maulik ji, this is on the basis of the current scenario. Suppose down the line in next six-month scenario got changed, then what we are saying may not be possible.”
Abhay Raj Singh, page 10 of the filed PDF · View the filing
Export mix can fluctuate quarter to quarter due to customer dispatch timing
p. 13
“So that number increases, but there are chances that in the next quarter, that customer has a very -- little bit quantities out of the agreement. So these are some of the variables which can lead to the export number a little bit up and down.”
Kushal Kumar Rana, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.